Биология ва тиббиёт муаммолари 2025, №4.1 (164)

Subject of the article

EVALUATINGTHE EFFECTIVENESS OF A NOVEL MULTIMODAL TREATMENT FOR AVASCULAR NECROSIS OF THE HEAD OF FEMUR OF POST COVID ETIOLOGY: A RETROSPECTIVE COHORT STUDY (97-100)

Authors

Sultanova Maksuma Khudayberganovna, Das Sharodiya, Mirzaakhmedov Farrukh Miradilovich, Kayumov Javohir, Juraeva Zulfiya Baratovna

Institution

Tashkent State Medical University, Republic of Uzbekistan, Tashkent

Abstract

Avascular necrosis (AVN) of the femoral head results from impaired blood supply, a condition increasingly observed in post-COVID-19 patients due to virus-induced microvascular damage. Conventional therapies often fail to address the vascular pathology. This retrospective cohort study, conducted from September 2020 to March 2024 in a tertiary hospital in Uzbekistan, included 350 post-COVID AVN patients divided into two groups. The case group (n=190) received standard conservative treatment plus hirudotherapy (2–3 times/week for 2 months), while the control group (n=160) received standard conservative care alone. Outcomes were evaluated through MRI staging and SF‑36 scores at baseline and every 6 months over 2 years. Results showed a significantly lower rate of femoral head collapse (10% vs. 34.4%), progression (20% vs. 51.3%), and surgery (3.2% vs. 10%) in the case group, with improved SF‑36 scores. This multimodal therapy demonstrates potential as an effective, non-surgical option for managing early-stage post-COVID AVN.

Key words

Hydrotherapy , COVID 19 , Femoral head necrosis, Risedronate , total hip replacement.

Literature

1. Agarwala S, Vijayvargiya M, Pandey P. Avascular necrosis as a part of long COVID-19. BMJ Case Rep. 2021;14(7):e243840. 2. Mifsud MJ, Zengin A, Prasannan L, Baboolal TG. COVID-19 and the risk of osteonecrosis: A scoping review. Bone Jt Open. 2022;3(6):465–471. 3. Vaishya R, Vaish A, Kumar A. Avascular necrosis of femoral head after COVID-19 infection: A position statement. Indian J Orthop. 2021;55(3):442–445. 4. Xu JJ, Zhang Q, Shan CY, et al. Early detection of steroid-induced femoral head osteonecrosis using MRI. Orthop Surg. 2014;6(3):162–167. 5. Mont MA, Zywiel MG, Marker DR, McGrath MS, Delanois RE. The natural history of untreated asymptomatic osteonecrosis of the femoral head: A systematic literature review. J Bone Joint Surg Am. 2010;92(12):2165–2170. 6. Rajagopal M, Balch Samora J, Ellis TJ. Evolving treatment strategies for osteonecrosis of the femoral head. Orthop Clin North Am. 2009;40(2):347–357. 7. Agarwala S, Vijayvargiya M, Pandey P, et al. Risedronate in the management of AVN of the femoral head. J Orthop Surg (Hong Kong). 2019;27(2):1–5. 8. Aldridge JM, Urbaniak JR. Avascular necrosis of the femoral head: the role of vascularized fibular grafting. Orthop Clin North Am. 2004;35(3):363–372 9. Motohashi M, Muto T, Saito M, et al. Evaluation of hip function and pain relief using MRI in patients with osteonecrosis. J Magn Reson Imaging. 2003;18(5):573–578. 10. Jones LC, Hungerford DS. Osteonecrosis: Etiology, diagnosis, and treatment. Curr Opin Rheumatol. 2004;16(4):443–449. 11. Chen CH, Chang JK, Lai KA, Hou SM. Treat-ment of steroid-induced femoral head osteonecrosis with alendronate in a rabbit model. J Orthop Res. 2005;23(5):1145–1151. 12. Okazaki S, Nagoya S, Matsumoto H, et al. Relationship between duration of steroid treatment and femoral head osteonecrosis in systemic lupus erythematosus. Lupus. 2008;17(6):641–645. 13. Cui Q, Wang GJ, Balian G. Steroid-induced adipogenesis in a pluripotential cell line from bone marrow. J Bone Joint Surg Am. 1997;79(7):1054–1063. 14. Yamamoto T, Schneider R, Iwamoto Y, Bullough PG. Rapid destruction of the femoral head in osteonecrosis: A radiological and histological study. J Bone Joint Surg Br. 1994;76(2):259–263 15. Hernigou P, Habibi A, Bachir D, Galacteros F. The natural history of asymptomatic osteonecrosis in adults with sickle cell disease. J Bone Joint Surg Am. 2006;88(12):2565–2572. 16. Becker WJ, Hwang K, Ryu JH. Hirudotherapy and osteonecrosis: Evidence and applications. Altern Ther Health Med. 2015;21(2):44–50. 17. Petrov TS, Ivanov IV, Staneva MP. Leech therapy in orthopaedics: Revival of an ancient method. Orthop Rev (Pavia). 2017;9(1):7458. 18. Baskova IP, Zavalova LL. Proteinase inhibitors from the medicinal leech Hirudo medicinalis. Biochemistry (Moscow). 2001;66(7):703–714. 19. Michalsen A, Roth M, Dobos G. Medicinal leech therapy: Historical perspectives and modern applications. Evid Based Complement Alternat Med. 2007;4(3):241–247. 20. Baskova IP, Kostrjukova ES, Dvoretsky AM. Leech saliva: A potent cocktail of antithrombotic, anti-inflammatory and bacteriostatic agents. J Biol Today’s World. 2013;2(7):360–365. 21. Smitaman E, Lawrence DA, Goodman SB, Maloney WJ, Lee KS. MRI of early osteonecrosis of the femoral head: A review. AJR Am J Roentgenol. 2012;199(3): 628–638. 22. Zhao DW, Yu M, Hu K, et al. Prevalence of femoral head osteonecrosis in China: A nationwide epidemiological survey. Chin Med J (Engl). 2015;128(21):2843–2850. 23. Rastogi R, Yadav P, Agrawal A, Jaiman R. Corticosteroid-induced osteonecrosis of the femoral head post-COVID-19: Incidence and outcome. J Clin Orthop Trauma. 2022;24:101725.